Aspiro Therapeutics, Inc.
Aspiro Therapeutics is dedicated to revolutionizing treatment for obstructive lung diseases such as asthma, COPD, and cystic fibrosis by developing advanced, disease-modifying therapies inspired by the natural lung protein CC16. Their innovative approach aims to target the underlying mechanisms of these conditions, offering safer and more effective treatment options to improve patient outcomes and prevent disease progression.
Industries
Nr. of Employees
small (1-50)
Aspiro Therapeutics, Inc.
Products
CC16-derived peptidomimetic therapeutic candidates
Preclinical-stage small peptidomimetic molecules inspired by active regions of the CC16 protein, designed to modulate integrin-mediated inflammatory cell recruitment to the lung and reduce airway inflammation and remodeling.
CC16-derived peptidomimetic therapeutic candidates
Preclinical-stage small peptidomimetic molecules inspired by active regions of the CC16 protein, designed to modulate integrin-mediated inflammatory cell recruitment to the lung and reduce airway inflammation and remodeling.
Services
Preclinical candidate design and optimization
Design and medicinal chemistry optimization of small peptidomimetic therapeutic candidates derived from CC16 active regions, including structural characterization and pharmacokinetic optimization.
High-throughput screening for anti-inflammatory activity
Cell-based, high-throughput assays that measure compound ability to inhibit leukocyte adhesion to endothelial cells and reduce inflammatory cell recruitment to the lung.
Preclinical efficacy and mechanistic studies in animal models
In vivo evaluation of candidate therapeutics in mouse models to measure effects on lung function, airway hyperresponsiveness, inflammatory cell infiltration, cytokine levels, mucus gene expression, and airway remodeling.
Aerosol delivery feasibility studies
Feasibility assessment of aerosolizing therapeutic candidates for pulmonary delivery to support development of respiratory administration routes.
Collaborative translational partnership and project management
Coordination with academic institutions, CROs, and other partners to advance translational programs efficiently under a virtual biotech operational model.
Preclinical candidate design and optimization
Design and medicinal chemistry optimization of small peptidomimetic therapeutic candidates derived from CC16 active regions, including structural characterization and pharmacokinetic optimization.
High-throughput screening for anti-inflammatory activity
Cell-based, high-throughput assays that measure compound ability to inhibit leukocyte adhesion to endothelial cells and reduce inflammatory cell recruitment to the lung.
Preclinical efficacy and mechanistic studies in animal models
In vivo evaluation of candidate therapeutics in mouse models to measure effects on lung function, airway hyperresponsiveness, inflammatory cell infiltration, cytokine levels, mucus gene expression, and airway remodeling.
Aerosol delivery feasibility studies
Feasibility assessment of aerosolizing therapeutic candidates for pulmonary delivery to support development of respiratory administration routes.
Collaborative translational partnership and project management
Coordination with academic institutions, CROs, and other partners to advance translational programs efficiently under a virtual biotech operational model.
Expertise Areas
- Preclinical development for respiratory therapeutics
- Medicinal chemistry and structure-activity optimization
- Respiratory disease biology and translational research
- In vivo respiratory disease modeling (mouse)
Key Technologies
- Peptidomimetic design and synthesis
- High-throughput cell-based screening assays
- Integrin-receptor binding assays
- Preclinical mouse disease models